Literature DB >> 14511802

Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study.

Thordur Sigmundsson1, Michael Maier, Brian K Toone, Steven C R Williams, Andrew Simmons, Kathryn Greenwood, Maria A Ron.   

Abstract

INTRODUCTION: Clinical, neuropsychological and functional neuroimaging studies in schizophrenia suggest impaired frontal lobe function, especially of the dorsolateral prefrontal region (DLPFR). This dysfunction has in particular been associated with negative or "deficit" symptoms. Despite these findings, morphological studies have failed to show consistent structural abnormalities in the frontal lobe. This may be because existing techniques are not sensitive enough to detect structural abnormalities or that dysfunction in the frontal lobe is caused by lesions elsewhere. We used volume-localised proton magnetic resonance spectroscopy (1H-MRS) to measure N-acetylaspartate (NAA), a neuronal marker, to evaluate the neuronal integrity of the dorsolateral prefrontal region in schizophrenic patients with persistent negative symptoms and in healthy comparison subjects.
METHOD: Twenty-five patients who fulfilled DSM-IV criteria for schizophrenia and met the criteria for the Deficit syndrome were compared to 26 healthy controls matched for age and gender. Bilateral proton MR spectra were collected from a 2-cm(3) volume in the dorsolateral prefrontal region and the absolute concentrations of N-acetylaspartate, choline (Cho) and creatine+phosphocreatine (Cr+PCr) were measured.
RESULTS: There was a significant negative correlation between severity of symptoms and NAA concentration in the schizophrenic patients. This was more marked for positive symptoms and for general psychopathology than for negative symptoms. There was also a significant correlation between NAA concentration and social functioning within the schizophrenic group. There were no significant differences between the two groups for the three metabolites.
CONCLUSIONS: The negative association between severity of symptoms and NAA in schizophrenic patients and an association of NAA with social functioning suggest that NAA may be an indicator of disease severity. The lack of significant mean difference in NAA between the two groups suggests that there is no marked neuronal loss in the dorsolateral prefrontal region in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511802     DOI: 10.1016/s0920-9964(02)00533-9

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  22 in total

Review 1.  Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.

Authors:  Deanna M Barch; Erin C Dowd
Journal:  Schizophr Bull       Date:  2010-06-21       Impact factor: 9.306

Review 2.  Recent advances in magnetic resonance neurospectroscopy.

Authors:  Yael Rosen; Robert E Lenkinski
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

Review 3.  Magnetic resonance imaging of myelin.

Authors:  Cornelia Laule; Irene M Vavasour; Shannon H Kolind; David K B Li; Tony L Traboulsee; G R Wayne Moore; Alex L MacKay
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

Review 4.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

Review 5.  Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Authors:  Joseph T Coyle
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 6.  Glutamate and schizophrenia: beyond the dopamine hypothesis.

Authors:  Joseph T Coyle
Journal:  Cell Mol Neurobiol       Date:  2006-06-14       Impact factor: 5.046

7.  Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.

Authors:  Meredith A Reid; Luke E Stoeckel; David M White; Kathy B Avsar; Mark S Bolding; N Shastry Akella; Robert C Knowlton; Jan A den Hollander; Adrienne C Lahti
Journal:  Biol Psychiatry       Date:  2010-06-08       Impact factor: 13.382

8.  Proton magnetic resonance spectroscopy (H-MRS) in chronic schizophrenia. A single-voxel study in three regions involved in a pathogenetic theory.

Authors:  F Granata; G Pandolfo; S Vinci; C Alafaci; N Settineri; R Morabito; A Pitrone; M Longo
Journal:  Neuroradiol J       Date:  2013-07-16

Review 9.  Neuroimaging schizophrenia: a picture is worth a thousand words, but is it saying anything important?

Authors:  Anthony O Ahmed; Peter F Buckley; Mona Hanna
Journal:  Curr Psychiatry Rep       Date:  2013-03       Impact factor: 5.285

10.  White matter alterations in deficit schizophrenia.

Authors:  Laura M Rowland; Elena A Spieker; Alan Francis; Peter B Barker; William T Carpenter; Robert W Buchanan
Journal:  Neuropsychopharmacology       Date:  2008-12-03       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.